Neuromuscular Disorders
Volume 17, Issue 6 , Pages 499-505 , June 2007

Issues in SMA clinical trial design: The International Coordinating Committee (ICC) for SMA Subcommittee on SMA Clinical Trial Design

  • P. Kaufmann

      Affiliations

    • Department of Neurology, Columbia University, New York, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • F. Muntoni

      Affiliations

    • Hammersmith Hospital, Imperial College, London, UK

References 

  1. Hirtz D, Iannaccone S, Heemskerk J, Gwinn-Hardy K, Moxley R, Rowland LP. Challenges opportunities in clinical trials for spinal muscular atrophy. Neurology. 2005;65:1352–1357
  2. Traynor BJ, Bruijn L, Conwit R, Beal F, et al. Neuroproctective agents for clinical trials in ALS: a systematic assessment. Neurology. 2006;67:20–27
  3. <http://www.fda.gov/cder/guidance/2353fnl.pdfFOoIM. Edited by; 1999/>.
  4. ctep.cancer.gov/forms/CTCAEv3.pdf.
  5. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. New York: Springer; 1998;
  6. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585–591
  7. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347:1425–1431
  8. Lacomblez L, Bensimon G, Leigh PN, et al. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology. 1996;47:S242–S250
  9. Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology. 2003;61:456–464
  10. Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology. 2006;66:324–330
  11. Hall CT. Dying doctor’s noble choice. Stricken S.F. neurologist enters own ‘placebo’ trial. San Francisco Chronicle 2005.
  12. Cheung YK. On the use of nonparametric curves in phase I trials with low toxicity tolerance. Biometrics. 2002;58:237–240
  13. Cheung YK, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics. 2000;56:1177–1182
  14. Cheung YK, Chappell R. A simple technique to evaluate model sensitivity in the continual reassessment method. Biometrics. 2002;58:671–674
  15. Levy G, Kaufmann P, Buchsbaum R, et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology. 2006;66:660–663
  16. Levin B. The utility of futility. Stroke. 2005;36:2331–2332
  17. Ensign LG, Gehan EA, Kamen DS, Thall PF. An optimal three-stage design for phase II clinical trials. Statistics in medicine. 1994;13:1727–1736
  18. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10
  19. <http://www.myozyme.com/PDF/mz_pi.pdf/>.
  20. Groeneveld GJ, van der Tweel I, Wokke JH, van den Berg LH. Sequential designs for clinical trials in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:202–207
  21. Groeneveld GJ, Veldink JH, van der Tweel I, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol. 2003;53:437–445
  22. Dubowitz V. Chaos in the classification of SMA: a possible resolution. Neuromuscul Disord. 1995;5:3–5
  23. Mellies U, Dohna-Schwake C, Stehling F, Voit T. Sleep disordered breathing in spinal muscular atrophy. Neuromuscul Disord. 2004;14:797–803
  24. Bromberg MB, Swoboda KJ. Motor unit number estimation in infants and children with spinal muscular atrophy. Muscle Nerve. 2002;25:445–447
  25. Bromberg MB, Swoboda KJ. Motor unit number estimation in infants and children with spinal muscular atrophy. Muscle Nerve. 2002;25:445–447
  26. Swoboda KJ, Prior TW, Scott CB, et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol. 2005;57:704–712
  27. Crawford TO. Concerns about the design of clinical trials for spinal muscular atrophy. Neuromuscul Disord. 2004;14:456–460
  28. Barois A, Mayer M, Desguerre I, et al. Spinal muscular atrophy. A 4-year prospective, multicenter, longitudinal study (168 cases). Bull Acad Natl Med. 2005;189:1181–1198
  29. Nelson L, Owens H, Hynan LS, Iannaccone ST, Amsmart G. The gross motor function measuretrade mark is a valid and sensitive outcome measure for spinal muscular atrophy. Neuromuscul Disord. 2006;
  30. Iannaccone ST. Outcome measures for pediatric spinal muscular atrophy. Arch Neurol. 2002;59:1445–1450
  31. Mercuri E, Messina S, Battini R, et al. Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study. Neuromuscul Disord. 2006;16:93–98
  32. Main M, Kairon H, Mercuri E, Muntoni F. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol. 2003;7:155–159
  33. Berard C, Payan C, Fermanian J, Girardot F. A motor function measurement scale for neuromuscular diseases – description and validation study. Rev Neurol (Paris). 2006;162:485–493
  34. Berard C, Payan C, Hodgkinson I, Fermanian J. A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord. 2005;15:463–470
  35. <http://www.amsmart.org//>.

PII: S0960-8966(06)00628-6

doi: 10.1016/j.nmd.2006.12.001

Neuromuscular Disorders
Volume 17, Issue 6 , Pages 499-505 , June 2007

Article Tools